Repeated use of antibiotics increases inflammatory bowel disease risk, study suggests Patients aged 40 to 60 years who had been prescribed antibiotics showed the highest risk for inflammatory bowel disease.…
Only 13% of IBD teams meet standards for pharmacist involvement A report by IBD UK, an alliance of professional bodies, has found that few inflammatory bowel disease services in the UK have enough expert pharmacists.…
Management of patients with inflammatory bowel disease: current and future treatments Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract and affects patients’ quality of life. Treatment of IBD involves induction and maintenance of remission. Current available therapies include anti-inflammatory aminosalicylates and corticoste…
Biosimilars and inflammatory bowel disease: a switch programme using CT-P13 How to plan and manage switching patients from a biologic to a biosimilar in inflammatory bowel disease, using the University Hospital Southampton NHS Foundation Trust’s experience as an example.…
Optimising therapy for inflammatory bowel disease How to tailor treatment for patients and ensure optimum management of Crohn’s disease and ulcerative colitis.…
